Skip to content
Screener

ANI Pharmaceuticals ANIP Q3 2025 earnings

Reported November 7, 2025 · Before market open

Revenue$227.8MMiss by $4.4M
EPS$2.04Beat by $0.30
Revenue estimate$232.2M
EPS estimate$1.74

Next report

Nov 6, 2026 (in 2 months)
Revenue estimate$280.1M
EPS estimate$2.12

Financials

Q3 2025

Income statement

See full
Revenue$227.8M+53.6%
Gross profit$134.4M+57.7%
Operating income$36.2M+277%
Net income$26.6M+210%
EPS (diluted)$1.13+189%

Balance sheet

See full
Cash & equivalents$262.6M+81.1%
Total debt$318.1M-0.6%
Total equity$505.8M+24.6%
Total assets$1.4B+9.4%

Cash flow

See full
Operating cash flow$44.1M+253%
CapEx$6.1M+26.8%
Free cash flow$38.0M+395%

Valuation & ratios

Valuation

as of 09/30/25
See full
Market cap$2.04B+62.7%
Enterprise value$2.1B+46.7%
P/E50.3×—
P/S2.5×+0.2×

Profitability

See full
Gross margin61.1%+1.4pp
Net margin4.9%+4.1pp
FCF margin18.8%+5.0pp

Returns & leverage

See full
Return on equity8.9%+7.7pp
Debt / equity0.6×-0.2×
Current ratio2.6×-0.2×

Segments

By product

See full
Cortrophin Gel$101.9M+93.8%
Generic pharmaceutical products$94.4M+20.6%
ILUVIEN and YUTIQ$16.6M+329%
Brands$10.7M—

By segment

See full
Rare Disease and Brands$129.1M—
Generics and Other$98.7M—

FAQ

When did ANI Pharmaceuticals report Q3 2025 earnings?
ANI Pharmaceuticals (ANIP) reported Q3 2025 earnings on November 7, 2025 before market open.
What were ANI Pharmaceuticals's Q3 2025 revenue and EPS?
ANI Pharmaceuticals reported revenue of $227.8M and eps of $2.04 for Q3 2025.
Did ANI Pharmaceuticals beat estimates in Q3 2025?
Revenue missed the consensus estimate of $232.2M by $4.4M. EPS beat the consensus estimate of $1.74 by $0.30.
How did ANI Pharmaceuticals's Q3 2025 results compare year-over-year?
Compared to the same quarter a year prior, revenue grew 53.6% from $148.3M a year earlier and eps grew 52.2% from $1.34.
Where can I find ANI Pharmaceuticals's Q3 2025 SEC filings?
You can read the 8-K earnings release (0001023024-25-000107) and the 10-Q periodic report (0001023024-25-000108) directly on SEC EDGAR. The filing index links above go to sec.gov.